Payment overview · 2025
General Payments
$58.73
2 reported records · 2 companies
Healthcare provider profile · identity verified
Kenan Kirkendall, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · WOODWARD, OK · NPI 1316949563
Verified facts
What the public records show
CMS Open Payments records show Kenan Kirkendall, D.O. received $58.73 in general payments during 2025 across 2 reported records.
Mannkind Corporation accounted for 72.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Mannkind Corporation | Unresolved — no canonical attribution shown | $42.50 | 72.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.23 | 27.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Education | $42.50 | 1 |
| Food and Beverage | $16.23 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $42.50 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 709 | 158 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 643 | 155 |
| Atorvastatin Calcium | Atorvastatin Calcium | 597 | 144 |
| Alendronate Sodium | Alendronate Sodium | 570 | 118 |
| Gabapentin | Gabapentin | 535 | 109 |
| Levothyroxine Sodium | Levothyroxine Sodium | 509 | 119 |
| Potassium Chloride | Potassium Chloride | 489 | 102 |
| Pantoprazole Sodium | Pantoprazole Sodium | 461 | 110 |
| Amlodipine Besylate | Amlodipine Besylate | 359 | 107 |
| Lisinopril | Lisinopril | 347 | 83 |
| Mounjaro | Tirzepatide | 332 | 54 |
| Eliquis | Apixaban | 330 | 52 |
| Metformin Hcl Er | Metformin Hcl | 317 | 73 |
| Tamsulosin Hcl | Tamsulosin Hcl | 298 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 283 | 72 |
| Omeprazole | Omeprazole | 271 | 68 |
| Furosemide | Furosemide | 266 | 49 |
| Montelukast Sodium | Montelukast Sodium | 264 | 64 |
| Ezetimibe | Ezetimibe | 262 | 57 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 253 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 238 | 59 |
| Jardiance | Empagliflozin | 182 | 31 |
| Allopurinol | Allopurinol | 180 | 39 |
| Donepezil Hcl | Donepezil Hcl | 174 | 36 |
| Carvedilol | Carvedilol | 171 | 37 |
| Famotidine | Famotidine | 171 | 38 |
| Metformin Hcl | Metformin Hcl | 171 | 49 |
| Duloxetine Hcl | Duloxetine Hcl | 168 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 157 | 42 |
| Ozempic | Semaglutide | 154 | 31 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 153 | 24 |
| Alprazolam | Alprazolam | 147 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 144 | 25 |
| Meloxicam | Meloxicam | 143 | 33 |
| Trulicity | Dulaglutide | 135 | 25 |
| Sertraline Hcl | Sertraline Hcl | 133 | 29 |
| Celecoxib | Celecoxib | 131 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 127 | 33 |
| Xarelto | Rivaroxaban | 119 | 18 |
| Simvastatin | Simvastatin | 116 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 108 | 62 |
| Farxiga | Dapagliflozin Propanediol | 100 | 21 |
| Januvia | Sitagliptin Phosphate | 99 | 19 |
| Prednisone | Prednisone | 98 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 92 | 32 |
| Tramadol Hcl | Tramadol Hcl | 92 | 25 |
| Cephalexin | Cephalexin | 89 | 64 |
| Ropinirole Hcl | Ropinirole Hcl | 88 | 18 |
| Buspirone Hcl | Buspirone Hcl | 84 | 15 |
| Methenamine Hippurate | Methenamine Hippurate | 81 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 80 | 26 |
| Amiodarone Hcl | Amiodarone Hcl | 78 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 75 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 74 | 17 |
| Levetiracetam | Levetiracetam | 74 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 72 | 21 |
| Trazodone Hcl | Trazodone Hcl | 71 | 23 |
| Propranolol Hcl Er | Propranolol Hcl | 68 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | 14 |
| Mirtazapine | Mirtazapine | 65 | 12 |
| Pregabalin | Pregabalin | 63 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 63 | 40 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 60 | 43 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 60 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 57 | 16 |
| Bupropion Hcl Sr | Bupropion Hcl | 56 | suppressed |
| Clonazepam | Clonazepam | 56 | suppressed |
| Repatha Sureclick | Evolocumab | 55 | suppressed |
| Sulfasalazine | Sulfasalazine | 54 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 53 | 15 |
| Bupropion Xl | Bupropion Hcl | 53 | 14 |
| Fentanyl | Fentanyl | 51 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 51 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 50 | suppressed |
| Telmisartan | Telmisartan | 50 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 47 | suppressed |
| Memantine Hcl | Memantine Hcl | 47 | suppressed |
| Spironolactone | Spironolactone | 46 | 12 |
| Topiramate | Topiramate | 46 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 45 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 45 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 43 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 29 |
| Sucralfate | Sucralfate | 41 | suppressed |
| Chlorthalidone | Chlorthalidone | 40 | suppressed |
| Estradiol | Estradiol | 39 | 13 |
| Ondansetron Odt | Ondansetron | 38 | 18 |
| Clonidine Hcl | Clonidine Hcl | 37 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 37 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 36 | 22 |
| Synthroid | Levothyroxine Sodium | 36 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 35 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 35 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 34 | suppressed |
| Entresto | Sacubitril/Valsartan | 33 | suppressed |
| Torsemide | Torsemide | 33 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 33 | 11 |
| Vascepa | Icosapent Ethyl | 33 | suppressed |
| Nabumetone | Nabumetone | 32 | suppressed |
| Novolog Flexpen | Insulin Aspart | 32 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 27 |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 29 | 28 |
| Atenolol | Atenolol | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 21 |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 22 |
| Baclofen | Baclofen | 27 | suppressed |
| Cefdinir | Cefdinir | 27 | 26 |
| Midodrine Hcl | Midodrine Hcl | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 26 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 26 | suppressed |
| Tradjenta | Linagliptin | 26 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 25 | suppressed |
| Digoxin | Digoxin | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | 12 |
| Labetalol Hcl | Labetalol Hcl | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Qulipta | Atogepant | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Dutasteride | Dutasteride | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 17 |
| Nortriptyline Hcl | Nortriptyline Hcl | 21 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | 12 |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 13 |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 14 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Ethosuximide | Ethosuximide | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Cefazolin Sodium | Cefazolin Sodium | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 12 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Azathioprine | Azathioprine | 11 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 11 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 11 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Silodosin | Silodosin | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $58.73 · 2 records | Mannkind Corporation | AFREZZA, VRAYLAR | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error